世界のJAK阻害剤ベース抗がん剤市場インサイト・予測（～2027年）

• 英文タイトル：Global JAK Inhibitor Based Cancer Drug Market Insights and Forecast to 2027

• レポートコード：QY2108PAL3981 • 出版社/出版日：QYResearch / 2021年8月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、89ページ • 納品方法：Eメール（納期：3日） • 産業分類：医薬品

• 販売価格（消費税別）

Single User	￥735,000 (USD4,900)	▷ お問い合わせ
Multi User	￥1,102,500 (USD7,350)	▷ お問い合わせ
Enterprise License	￥1,470,000 (USD9,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

本調査資料はJAK阻害剤ベース抗がん剤の世界市場の現状について調査・分析し、2027年までの市場を予測しました。JAK阻害剤ベース抗がん剤の世界市場概要、メーカー別の競争状況と市場シェア、種類別市場規模（トファシチニブ、ルキソリチニブ、バリシチニブ）、用途別市場規模（関節リウマチ（RA）、真性多血症（PCV）、骨髄線維症（MF））、主要地域別市場規模（北米・アメリカ、ヨーロッパ、アジア・日本・中国・インド、中南米、中東・アフリカ）、関連企業の情報、バリューチェーン・販売チャネル、市場動向などを収録しています。 ・JAK阻害剤ベース抗がん剤の世界市場概要 ・メーカー別の競争状況、市場シェア ・JAK阻害剤ベース抗がん剤の種類別市場規模：トファシチニブ、ルキソリチニブ、バリシチニブ ・JAK阻害剤ベース抗がん剤の用途別市場規模：関節リウマチ（RA）、真性多血症（PCV）、骨髄線維症（MF） ・北米のJAK阻害剤ベース抗がん剤市場規模2016-2027：種類別、用途別、国別（アメリカ、カナダ） ・ヨーロッパのJAK阻害剤ベース抗がん剤市場規模2016-2027：種類別、用途別、国別（ドイツ、フランス、イギリス） ・アジアのJAK阻害剤ベース抗がん剤市場規模2016-2027：種類別、用途別、国別（日本、中国、インド、韓国） ・中南米のJAK阻害剤ベース抗がん剤市場規模2016-2027：種類別、用途別、国別（メキシコ、ブラジル） ・中東・アフリカのJAK阻害剤ベース抗がん剤市場規模2016-2027：種類別、用途別、国別（トルコ、サウジアラビア） ・企業情報：Pfizer、Incyte、Novartis、Eli Lilly ・JAK阻害剤ベース抗がん剤のバリューチェーン・販売チャネル分析 ・JAK阻害剤ベース抗がん剤の世界市場動向

JAK inhibitor I is a JAK1/2/3 inhibitor that decreased cell proliferation in breast cancer cells, increased apoptosis in esophageal squamous cell carcinoma cancer stem cells, inhibited STAT3 phosphorylation in HCC cells, and, in combination with cisplatin, decreased PD-L1 expression in prostate cancer cells.

Market Analysis and Insights: Global JAK Inhibitor Based Cancer Drug Market
The global JAK Inhibitor Based Cancer Drug market is valued at US$ XX million in 2020. The market size will reach US$ XX million by the end of 2027, growing at a CAGR of XX% during 2021-2027.

Global JAK Inhibitor Based Cancer Drug Scope and Segment
JAK Inhibitor Based Cancer Drug market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global JAK Inhibitor Based Cancer Drug market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2016-2027.

Segment by Type
Tofacitinib
Ruxolitinib
Baricitinib

Segment by Application
Rheumatoid Arthritis (RA)
Polycythemia Vera (PCV)
Myelofibrosis (MF)

By Company
Pfizer
Incyte
Novartis
Eli Lilly

By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE

レポート目次

---

1 Study Coverage
1.1 JAK Inhibitor Based Cancer Drug Product Introduction
1.2 Market by Type
1.2.1 Global JAK Inhibitor Based Cancer Drug Market Size Growth Rate by Type
1.2.2 Tofacitinib
1.2.3 Ruxolitinib
1.2.4 Baricitinib
1.3 Market by Application
1.3.1 Global JAK Inhibitor Based Cancer Drug Market Size Growth Rate by Application
1.3.2 Rheumatoid Arthritis (RA)
1.3.3 Polycythemia Vera (PCV)
1.3.4 Myelofibrosis (MF)
1.4 Study Objectives
1.5 Years Considered

2 Executive Summary
2.1 Global JAK Inhibitor Based Cancer Drug Sales Estimates and Forecasts 2016-2027
2.2 Global JAK Inhibitor Based Cancer Drug Revenue Estimates and Forecasts 2016-2027
2.3 Global JAK Inhibitor Based Cancer Drug Revenue by Region: 2016 VS 2021 VS 2027
2.4 Global Top JAK Inhibitor Based Cancer Drug Regions by Sales
2.4.1 Global Top JAK Inhibitor Based Cancer Drug Regions by Sales (2016-2021)
2.4.2 Global Top JAK Inhibitor Based Cancer Drug Regions by Sales (2022-2027)
2.5 Global Top JAK Inhibitor Based Cancer Drug Regions by Revenue
2.5.1 Global Top JAK Inhibitor Based Cancer Drug Regions by Revenue (2016-2021)
2.5.2 Global Top JAK Inhibitor Based Cancer Drug Regions by Revenue (2022-2027)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa

3 Competition by Manufacturers
3.1 Global JAK Inhibitor Based Cancer Drug Sales by Manufacturers
3.1.1 Global Top JAK Inhibitor Based Cancer Drug Manufacturers by Sales (2016-2021)
3.1.2 Global Top JAK Inhibitor Based Cancer Drug Manufacturers Market Share by Sales (2016-2021)
3.1.3 Global Top 10 and Top 5 Companies by JAK Inhibitor Based Cancer Drug Sales in 2020
3.2 Global JAK Inhibitor Based Cancer Drug Revenue by Manufacturers
3.2.1 Global Top JAK Inhibitor Based Cancer Drug Manufacturers by Revenue (2016-2021)
3.2.2 Global Top JAK Inhibitor Based Cancer Drug Manufacturers Market Share by Revenue (2016-2021)
3.2.3 Global Top 10 and Top 5 Companies by JAK Inhibitor Based Cancer Drug Revenue in 2020
3.3 Global JAK Inhibitor Based Cancer Drug Sales Price by Manufacturers
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global JAK Inhibitor Based Cancer Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global JAK Inhibitor Based Cancer Drug Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type
4.1 Global JAK Inhibitor Based Cancer Drug Sales by Type
4.1.1 Global JAK Inhibitor Based Cancer Drug Historical Sales by Type (2016-2021)
4.1.2 Global JAK Inhibitor Based Cancer Drug Forecasted Sales by Type (2022-2027)
4.1.3 Global JAK Inhibitor Based Cancer Drug Sales Market Share by Type (2016-2027)
4.2 Global JAK Inhibitor Based Cancer Drug Revenue by Type
4.2.1 Global JAK Inhibitor Based Cancer Drug Historical Revenue by Type (2016-2021)
4.2.2 Global JAK Inhibitor Based Cancer Drug Forecasted Revenue by Type (2022-2027)
4.2.3 Global JAK Inhibitor Based Cancer Drug Revenue Market Share by Type (2016-2027)
4.3 Global JAK Inhibitor Based Cancer Drug Price by Type
4.3.1 Global JAK Inhibitor Based Cancer Drug Price by Type (2016-2021)
4.3.2 Global JAK Inhibitor Based Cancer Drug Price Forecast by Type (2022-2027)

5 Market Size by Application
5.1 Global JAK Inhibitor Based Cancer Drug Sales by Application
5.1.1 Global JAK Inhibitor Based Cancer Drug Historical Sales by Application (2016-2021)
5.1.2 Global JAK Inhibitor Based Cancer Drug Forecasted Sales by Application (2022-2027)
5.1.3 Global JAK Inhibitor Based Cancer Drug Sales Market Share by Application (2016-2027)
5.2 Global JAK Inhibitor Based Cancer Drug Revenue by Application
5.2.1 Global JAK Inhibitor Based Cancer Drug Historical Revenue by Application (2016-2021)
5.2.2 Global JAK Inhibitor Based Cancer Drug Forecasted Revenue by Application (2022-2027)
5.2.3 Global JAK Inhibitor Based Cancer Drug Revenue Market Share by Application (2016-2027)
5.3 Global JAK Inhibitor Based Cancer Drug Price by Application
5.3.1 Global JAK Inhibitor Based Cancer Drug Price by Application (2016-2021)
5.3.2 Global JAK Inhibitor Based Cancer Drug Price Forecast by Application (2022-2027)

6 North America
6.1 North America JAK Inhibitor Based Cancer Drug Market Size by Type
6.1.1 North America JAK Inhibitor Based Cancer Drug Sales by Type (2016-2027)
6.1.2 North America JAK Inhibitor Based Cancer Drug Revenue by Type (2016-2027)
6.2 North America JAK Inhibitor Based Cancer Drug Market Size by Application
6.2.1 North America JAK Inhibitor Based Cancer Drug Sales by Application (2016-2027)
6.2.2 North America JAK Inhibitor Based Cancer Drug Revenue by Application (2016-2027)
6.3 North America JAK Inhibitor Based Cancer Drug Market Size by Country
6.3.1 North America JAK Inhibitor Based Cancer Drug Sales by Country (2016-2027)
6.3.2 North America JAK Inhibitor Based Cancer Drug Revenue by Country (2016-2027)
6.3.3 United States
6.3.4 Canada

7 Europe
7.1 Europe JAK Inhibitor Based Cancer Drug Market Size by Type
7.1.1 Europe JAK Inhibitor Based Cancer Drug Sales by Type (2016-2027)
7.1.2 Europe JAK Inhibitor Based Cancer Drug Revenue by Type (2016-2027)
7.2 Europe JAK Inhibitor Based Cancer Drug Market Size by Application
7.2.1 Europe JAK Inhibitor Based Cancer Drug Sales by Application (2016-2027)
7.2.2 Europe JAK Inhibitor Based Cancer Drug Revenue by Application (2016-2027)
7.3 Europe JAK Inhibitor Based Cancer Drug Market Size by Country
7.3.1 Europe JAK Inhibitor Based Cancer Drug Sales by Country (2016-2027)
7.3.2 Europe JAK Inhibitor Based Cancer Drug Revenue by Country (2016-2027)
7.3.3 Germany
7.3.4 France
7.3.5 U.K.
7.3.6 Italy
7.3.7 Russia

8 Asia Pacific
8.1 Asia Pacific JAK Inhibitor Based Cancer Drug Market Size by Type
8.1.1 Asia Pacific JAK Inhibitor Based Cancer Drug Sales by Type (2016-2027)
8.1.2 Asia Pacific JAK Inhibitor Based Cancer Drug Revenue by Type (2016-2027)
8.2 Asia Pacific JAK Inhibitor Based Cancer Drug Market Size by Application
8.2.1 Asia Pacific JAK Inhibitor Based Cancer Drug Sales by Application (2016-2027)
8.2.2 Asia Pacific JAK Inhibitor Based Cancer Drug Revenue by Application (2016-2027)
8.3 Asia Pacific JAK Inhibitor Based Cancer Drug Market Size by Region
8.3.1 Asia Pacific JAK Inhibitor Based Cancer Drug Sales by Region (2016-2027)
8.3.2 Asia Pacific JAK Inhibitor Based Cancer Drug Revenue by Region (2016-2027)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 China Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia

9 Latin America
9.1 Latin America JAK Inhibitor Based Cancer Drug Market Size by Type
9.1.1 Latin America JAK Inhibitor Based Cancer Drug Sales by Type (2016-2027)
9.1.2 Latin America JAK Inhibitor Based Cancer Drug Revenue by Type (2016-2027)
9.2 Latin America JAK Inhibitor Based Cancer Drug Market Size by Application
9.2.1 Latin America JAK Inhibitor Based Cancer Drug Sales by Application (2016-2027)
9.2.2 Latin America JAK Inhibitor Based Cancer Drug Revenue by Application (2016-2027)
9.3 Latin America JAK Inhibitor Based Cancer Drug Market Size by Country
9.3.1 Latin America JAK Inhibitor Based Cancer Drug Sales by Country (2016-2027)
9.3.2 Latin America JAK Inhibitor Based Cancer Drug Revenue by Country (2016-2027)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina
9.3.6 Colombia

10 Middle East and Africa
10.1 Middle East and Africa JAK Inhibitor Based Cancer Drug Market Size by Type
10.1.1 Middle East and Africa JAK Inhibitor Based Cancer Drug Sales by Type (2016-2027)
10.1.2 Middle East and Africa JAK Inhibitor Based Cancer Drug Revenue by Type (2016-2027)
10.2 Middle East and Africa JAK Inhibitor Based Cancer Drug Market Size by Application
10.2.1 Middle East and Africa JAK Inhibitor Based Cancer Drug Sales by Application (2016-2027)
10.2.2 Middle East and Africa JAK Inhibitor Based Cancer Drug Revenue by Application (2016-2027)
10.3 Middle East and Africa JAK Inhibitor Based Cancer Drug Market Size by Country
10.3.1 Middle East and Africa JAK Inhibitor Based Cancer Drug Sales by Country (2016-2027)
10.3.2 Middle East and Africa JAK Inhibitor Based Cancer Drug Revenue by Country (2016-2027)
10.3.3 Turkey
10.3.4 Saudi Arabia

11 Company Profiles
11.1 Pfizer
11.1.1 Pfizer Corporation Information
11.1.2 Pfizer Overview
11.1.3 Pfizer JAK Inhibitor Based Cancer Drug Sales, Price, Revenue and Gross Margin (2016-2021)
11.1.4 Pfizer JAK Inhibitor Based Cancer Drug Product Description
11.1.5 Pfizer Recent Developments
11.2 Incyte
11.2.1 Incyte Corporation Information
11.2.2 Incyte Overview
11.2.3 Incyte JAK Inhibitor Based Cancer Drug Sales, Price, Revenue and Gross Margin (2016-2021)
11.2.4 Incyte JAK Inhibitor Based Cancer Drug Product Description
11.2.5 Incyte Recent Developments
11.3 Novartis
11.3.1 Novartis Corporation Information
11.3.2 Novartis Overview
11.3.3 Novartis JAK Inhibitor Based Cancer Drug Sales, Price, Revenue and Gross Margin (2016-2021)
11.3.4 Novartis JAK Inhibitor Based Cancer Drug Product Description
11.3.5 Novartis Recent Developments
11.4 Eli Lilly
11.4.1 Eli Lilly Corporation Information
11.4.2 Eli Lilly Overview
11.4.3 Eli Lilly JAK Inhibitor Based Cancer Drug Sales, Price, Revenue and Gross Margin (2016-2021)
11.4.4 Eli Lilly JAK Inhibitor Based Cancer Drug Product Description
11.4.5 Eli Lilly Recent Developments

12 Value Chain and Sales Channels Analysis
12.1 JAK Inhibitor Based Cancer Drug Value Chain Analysis
12.2 JAK Inhibitor Based Cancer Drug Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 JAK Inhibitor Based Cancer Drug Production Mode & Process
12.4 JAK Inhibitor Based Cancer Drug Sales and Marketing
12.4.1 JAK Inhibitor Based Cancer Drug Sales Channels
12.4.2 JAK Inhibitor Based Cancer Drug Distributors
12.5 JAK Inhibitor Based Cancer Drug Customers

13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 JAK Inhibitor Based Cancer Drug Industry Trends
13.2 JAK Inhibitor Based Cancer Drug Market Drivers
13.3 JAK Inhibitor Based Cancer Drug Market Challenges
13.4 JAK Inhibitor Based Cancer Drug Market Restraints

14 Key Findings in The Global JAK Inhibitor Based Cancer Drug Study

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Tables
Table 1. Global JAK Inhibitor Based Cancer Drug Market Size Growth Rate by Type, 2016 VS 2021 VS 2027 (US$ Million)
Table 2. Major Manufacturers of Tofacitinib
Table 3. Major Manufacturers of Ruxolitinib
Table 4. Major Manufacturers of Baricitinib
Table 5. Global JAK Inhibitor Based Cancer Drug Market Size Growth Rate by Application, 2016 VS 2021 VS 2027 (US$ Million)
Table 6. Global JAK Inhibitor Based Cancer Drug Revenue by Region: 2016 VS 2021 VS 2027 (US$ Million)
Table 7. Global JAK Inhibitor Based Cancer Drug Sales by Region (2016-2021) & (K Units)
Table 8. Global JAK Inhibitor Based Cancer Drug Sales Market Share by Region (2016-2021)
Table 9. Global JAK Inhibitor Based Cancer Drug Sales by Region (2022-2027) & (K Units)
Table 10. Global JAK Inhibitor Based Cancer Drug Sales Market Share by Region (2022-2027)
Table 11. Global JAK Inhibitor Based Cancer Drug Revenue by Region (2016-2021) & (US$ Million)
Table 12. Global JAK Inhibitor Based Cancer Drug Revenue Market Share by Region (2016-2021)
Table 13. Global JAK Inhibitor Based Cancer Drug Revenue by Region (2022-2027) & (US$ Million)
Table 14. Global JAK Inhibitor Based Cancer Drug Revenue Market Share by Region (2022-2027)
Table 15. Global JAK Inhibitor Based Cancer Drug Sales by Manufacturers (2016-2021) & (K Units)
Table 16. Global JAK Inhibitor Based Cancer Drug Sales Share by Manufacturers (2016-2021)
Table 17. Global JAK Inhibitor Based Cancer Drug Revenue by Manufacturers (2016-2021) & (US$ Million)
Table 18. Global JAK Inhibitor Based Cancer Drug Revenue Share by Manufacturers (2016-2021)
Table 19. JAK Inhibitor Based Cancer Drug Price by Manufacturers 2016-2021 (US$/Unit)
Table 20. Global JAK Inhibitor Based Cancer Drug Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 21. Global JAK Inhibitor Based Cancer Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in JAK Inhibitor Based Cancer Drug as of 2020)
Table 22. JAK Inhibitor Based Cancer Drug Manufacturing Base Distribution and Headquarters
Table 23. Manufacturers JAK Inhibitor Based Cancer Drug Product Offered
Table 24. Date of Manufacturers Enter into JAK Inhibitor Based Cancer Drug Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global JAK Inhibitor Based Cancer Drug Sales by Type (2016-2021) & (K Units)
Table 27. Global JAK Inhibitor Based Cancer Drug Sales by Type (2022-2027) & (K Units)
Table 28. Global JAK Inhibitor Based Cancer Drug Sales Share by Type (2016-2021)
Table 29. Global JAK Inhibitor Based Cancer Drug Sales Share by Type (2022-2027)
Table 30. Global JAK Inhibitor Based Cancer Drug Revenue by Type (2016-2021) & (US$ Million)
Table 31. Global JAK Inhibitor Based Cancer Drug Revenue by Type (2022-2027) & (US$ Million)
Table 32. Global JAK Inhibitor Based Cancer Drug Revenue Share by Type (2016-2021)
Table 33. Global JAK Inhibitor Based Cancer Drug Revenue Share by Type (2022-2027)
Table 34. JAK Inhibitor Based Cancer Drug Price by Type (2016-2021) & (US$/Unit)
Table 35. Global JAK Inhibitor Based Cancer Drug Price Forecast by Type (2022-2027) & (US$/Unit)
Table 36. Global JAK Inhibitor Based Cancer Drug Sales by Application (2016-2021) & (K Units)
Table 37. Global JAK Inhibitor Based Cancer Drug Sales by Application (2022-2027) & (K Units)
Table 38. Global JAK Inhibitor Based Cancer Drug Sales Share by Application (2016-2021)
Table 39. Global JAK Inhibitor Based Cancer Drug Sales Share by Application (2022-2027)
Table 40. Global JAK Inhibitor Based Cancer Drug Revenue by Application (2016-2021) & (US$ Million)
Table 41. Global JAK Inhibitor Based Cancer Drug Revenue by Application (2022-2027) & (US$ Million)
Table 42. Global JAK Inhibitor Based Cancer Drug Revenue Share by Application (2016-2021)
Table 43. Global JAK Inhibitor Based Cancer Drug Revenue Share by Application (2022-2027)
Table 44. JAK Inhibitor Based Cancer Drug Price by Application (2016-2021) & (US$/Unit)
Table 45. Global JAK Inhibitor Based Cancer Drug Price Forecast by Application (2022-2027) & (US$/Unit)
Table 46. North America JAK Inhibitor Based Cancer Drug Sales by Type (2016-2021) & (K Units)
Table 47. North America JAK Inhibitor Based Cancer Drug Sales by Type (2022-2027) & (K Units)
Table 48. North America JAK Inhibitor Based Cancer Drug Revenue by Type (2016-2021) & (US$ Million)
Table 49. North America JAK Inhibitor Based Cancer Drug Revenue by Type (2022-2027) & (US$ Million)
Table 50. North America JAK Inhibitor Based Cancer Drug Sales by Application (2016-2021) & (K Units)
Table 51. North America JAK Inhibitor Based Cancer Drug Sales by Application (2022-2027) & (K Units)
Table 52. North America JAK Inhibitor Based Cancer Drug Revenue by Application (2016-2021) & (US$ Million)
Table 53. North America JAK Inhibitor Based Cancer Drug Revenue by Application (2022-2027) & (US$ Million)
Table 54. North America JAK Inhibitor Based Cancer Drug Sales by Country (2016-2021) & (K Units)
Table 55. North America JAK Inhibitor Based Cancer Drug Sales by Country (2022-2027) & (K Units)
Table 56. North America JAK Inhibitor Based Cancer Drug Revenue by Country (2016-2021) & (US$ Million)
Table 57. North America JAK Inhibitor Based Cancer Drug Revenue by Country (2022-2027) & (US$ Million)
Table 58. Europe JAK Inhibitor Based Cancer Drug Sales by Type (2016-2021) & (K Units)
Table 59. Europe JAK Inhibitor Based Cancer Drug Sales by Type (2022-2027) & (K Units)
Table 60. Europe JAK Inhibitor Based Cancer Drug Revenue by Type (2016-2021) & (US$ Million)
Table 61. Europe JAK Inhibitor Based Cancer Drug Revenue by Type (2022-2027) & (US$ Million)
Table 62. Europe JAK Inhibitor Based Cancer Drug Sales by Application (2016-2021) & (K Units)
Table 63. Europe JAK Inhibitor Based Cancer Drug Sales by Application (2022-2027) & (K Units)
Table 64. Europe JAK Inhibitor Based Cancer Drug Revenue by Application (2016-2021) & (US$ Million)
Table 65. Europe JAK Inhibitor Based Cancer Drug Revenue by Application (2022-2027) & (US$ Million)
Table 66. Europe JAK Inhibitor Based Cancer Drug Sales by Country (2016-2021) & (K Units)
Table 67. Europe JAK Inhibitor Based Cancer Drug Sales by Country (2022-2027) & (K Units)
Table 68. Europe JAK Inhibitor Based Cancer Drug Revenue by Country (2016-2021) & (US$ Million)
Table 69. Europe JAK Inhibitor Based Cancer Drug Revenue by Country (2022-2027) & (US$ Million)
Table 70. Asia Pacific JAK Inhibitor Based Cancer Drug Sales by Type (2016-2021) & (K Units)
Table 71. Asia Pacific JAK Inhibitor Based Cancer Drug Sales by Type (2022-2027) & (K Units)
Table 72. Asia Pacific JAK Inhibitor Based Cancer Drug Revenue by Type (2016-2021) & (US$ Million)
Table 73. Asia Pacific JAK Inhibitor Based Cancer Drug Revenue by Type (2022-2027) & (US$ Million)
Table 74. Asia Pacific JAK Inhibitor Based Cancer Drug Sales by Application (2016-2021) & (K Units)
Table 75. Asia Pacific JAK Inhibitor Based Cancer Drug Sales by Application (2022-2027) & (K Units)
Table 76. Asia Pacific JAK Inhibitor Based Cancer Drug Revenue by Application (2016-2021) & (US$ Million)
Table 77. Asia Pacific JAK Inhibitor Based Cancer Drug Revenue by Application (2022-2027) & (US$ Million)
Table 78. Asia Pacific JAK Inhibitor Based Cancer Drug Sales by Region (2016-2021) & (K Units)
Table 79. Asia Pacific JAK Inhibitor Based Cancer Drug Sales by Region (2022-2027) & (K Units)
Table 80. Asia Pacific JAK Inhibitor Based Cancer Drug Revenue by Region (2016-2021) & (US$ Million)
Table 81. Asia Pacific JAK Inhibitor Based Cancer Drug Revenue by Region (2022-2027) & (US$ Million)
Table 82. Latin America JAK Inhibitor Based Cancer Drug Sales by Type (2016-2021) & (K Units)
Table 83. Latin America JAK Inhibitor Based Cancer Drug Sales by Type (2022-2027) & (K Units)
Table 84. Latin America JAK Inhibitor Based Cancer Drug Revenue by Type (2016-2021) & (US$ Million)
Table 85. Latin America JAK Inhibitor Based Cancer Drug Revenue by Type (2022-2027) & (US$ Million)
Table 86. Latin America JAK Inhibitor Based Cancer Drug Sales by Application (2016-2021) & (K Units)
Table 87. Latin America JAK Inhibitor Based Cancer Drug Sales by Application (2022-2027) & (K Units)
Table 88. Latin America JAK Inhibitor Based Cancer Drug Revenue by Application (2016-2021) & (US$ Million)
Table 89. Latin America JAK Inhibitor Based Cancer Drug Revenue by Application (2022-2027) & (US$ Million)
Table 90. Latin America JAK Inhibitor Based Cancer Drug Sales by Country (2016-2021) & (K Units)
Table 91. Latin America JAK Inhibitor Based Cancer Drug Sales by Country (2022-2027) & (K Units)
Table 92. Latin America JAK Inhibitor Based Cancer Drug Revenue by Country (2016-2021) & (US$ Million)
Table 93. Latin America JAK Inhibitor Based Cancer Drug Revenue by Country (2022-2027) & (US$ Million)
Table 94. Middle East and Africa JAK Inhibitor Based Cancer Drug Sales by Type (2016-2021) & (K Units)
Table 95. Middle East and Africa JAK Inhibitor Based Cancer Drug Sales by Type (2022-2027) & (K Units)
Table 96. Middle East and Africa JAK Inhibitor Based Cancer Drug Revenue by Type (2016-2021) & (US$ Million)
Table 97. Middle East and Africa JAK Inhibitor Based Cancer Drug Revenue by Type (2022-2027) & (US$ Million)
Table 98. Middle East and Africa JAK Inhibitor Based Cancer Drug Sales by Application (2016-2021) & (K Units)
Table 99. Middle East and Africa JAK Inhibitor Based Cancer Drug Sales by Application (2022-2027) & (K Units)
Table 100. Middle East and Africa JAK Inhibitor Based Cancer Drug Revenue by Application (2016-2021) & (US$ Million)
Table 101. Middle East and Africa JAK Inhibitor Based Cancer Drug Revenue by Application (2022-2027) & (US$ Million)
Table 102. Middle East and Africa JAK Inhibitor Based Cancer Drug Sales by Country (2016-2021) & (K Units)
Table 103. Middle East and Africa JAK Inhibitor Based Cancer Drug Sales by Country (2022-2027) & (K Units)
Table 104. Middle East and Africa JAK Inhibitor Based Cancer Drug Revenue by Country (2016-2021) & (US$ Million)
Table 105. Middle East and Africa JAK Inhibitor Based Cancer Drug Revenue by Country (2022-2027) & (US$ Million)
Table 106. Pfizer Corporation Information
Table 107. Pfizer Description and Major Businesses
Table 108. Pfizer JAK Inhibitor Based Cancer Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021)
Table 109. Pfizer JAK Inhibitor Based Cancer Drug Product
Table 110. Pfizer Recent Developments
Table 111. Incyte Corporation Information
Table 112. Incyte Description and Major Businesses
Table 113. Incyte JAK Inhibitor Based Cancer Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021)
Table 114. Incyte JAK Inhibitor Based Cancer Drug Product
Table 115. Incyte Recent Developments
Table 116. Novartis Corporation Information
Table 117. Novartis Description and Major Businesses
Table 118. Novartis JAK Inhibitor Based Cancer Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021)
Table 119. Novartis JAK Inhibitor Based Cancer Drug Product
Table 120. Novartis Recent Developments
Table 121. Eli Lilly Corporation Information
Table 122. Eli Lilly Description and Major Businesses
Table 123. Eli Lilly JAK Inhibitor Based Cancer Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021)
Table 124. Eli Lilly JAK Inhibitor Based Cancer Drug Product
Table 125. Eli Lilly Recent Developments
Table 126. Key Raw Materials Lists
Table 127. Raw Materials Key Suppliers Lists
Table 128. JAK Inhibitor Based Cancer Drug Distributors List
Table 129. JAK Inhibitor Based Cancer Drug Customers List
Table 130. JAK Inhibitor Based Cancer Drug Market Trends
Table 131. JAK Inhibitor Based Cancer Drug Market Drivers
Table 132. JAK Inhibitor Based Cancer Drug Market Challenges
Table 133. JAK Inhibitor Based Cancer Drug Market Restraints
Table 134. Research Programs/Design for This Report
Table 135. Key Data Information from Secondary Sources
Table 136. Key Data Information from Primary Sources
List of Figures
Figure 1. JAK Inhibitor Based Cancer Drug Product Picture
Figure 2. Global JAK Inhibitor Based Cancer Drug Market Share by Type in 2020 & 2027
Figure 3. Tofacitinib Product Picture
Figure 4. Ruxolitinib Product Picture
Figure 5. Baricitinib Product Picture
Figure 6. Global JAK Inhibitor Based Cancer Drug Market Share by Application in 2020 & 2027
Figure 7. Rheumatoid Arthritis (RA)
Figure 8. Polycythemia Vera (PCV)
Figure 9. Myelofibrosis (MF)
Figure 10. JAK Inhibitor Based Cancer Drug Report Years Considered
Figure 11. Global JAK Inhibitor Based Cancer Drug Sales 2016-2027 (K Units)
Figure 12. Global JAK Inhibitor Based Cancer Drug Revenue, (US$ Million), 2016 VS 2021 VS 2027
Figure 13. Global JAK Inhibitor Based Cancer Drug Revenue 2016-2027 (US$ Million)
Figure 14. Global JAK Inhibitor Based Cancer Drug Revenue Market Share by Region in Percentage: 2020 Versus 2027
Figure 15. Global JAK Inhibitor Based Cancer Drug Sales Market Share by Region (2016-2021)
Figure 16. Global JAK Inhibitor Based Cancer Drug Sales Market Share by Region (2022-2027)
Figure 17. North America JAK Inhibitor Based Cancer Drug Sales YoY (2016-2027) & (K Units)
Figure 18. North America JAK Inhibitor Based Cancer Drug Revenue YoY (2016-2027) & (US$ Million)
Figure 19. Europe JAK Inhibitor Based Cancer Drug Sales YoY (2016-2027) & (K Units)
Figure 20. Europe JAK Inhibitor Based Cancer Drug Revenue YoY (2016-2027) & (US$ Million)
Figure 21. Asia-Pacific JAK Inhibitor Based Cancer Drug Sales YoY (2016-2027) & (K Units)
Figure 22. Asia-Pacific JAK Inhibitor Based Cancer Drug Revenue YoY (2016-2027) & (US$ Million)
Figure 23. Latin America JAK Inhibitor Based Cancer Drug Sales YoY (2016-2027) & (K Units)
Figure 24. Latin America JAK Inhibitor Based Cancer Drug Revenue YoY (2016-2027) & (US$ Million)
Figure 25. Middle East & Africa JAK Inhibitor Based Cancer Drug Sales YoY (2016-2027) & (K Units)
Figure 26. Middle East & Africa JAK Inhibitor Based Cancer Drug Revenue YoY (2016-2027) & (US$ Million)
Figure 27. The Top 10 and Top 5 Players Market Share by JAK Inhibitor Based Cancer Drug Sales in 2020
Figure 28. The Top 10 and Top 5 Players Market Share by JAK Inhibitor Based Cancer Drug Revenue in 2020
Figure 29. JAK Inhibitor Based Cancer Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2016 VS 2020
Figure 30. Global JAK Inhibitor Based Cancer Drug Sales Market Share by Type (2016-2027)
Figure 31. Global JAK Inhibitor Based Cancer Drug Revenue Market Share by Type (2016-2027)
Figure 32. Global JAK Inhibitor Based Cancer Drug Sales Market Share by Application (2016-2027)
Figure 33. Global JAK Inhibitor Based Cancer Drug Revenue Market Share by Application (2016-2027)
Figure 34. North America JAK Inhibitor Based Cancer Drug Sales Market Share by Type (2016-2027)
Figure 35. North America JAK Inhibitor Based Cancer Drug Revenue Market Share by Type (2016-2027)
Figure 36. North America JAK Inhibitor Based Cancer Drug Sales Market Share by Application (2016-2027)
Figure 37. North America JAK Inhibitor Based Cancer Drug Revenue Market Share by Application (2016-2027)
Figure 38. North America JAK Inhibitor Based Cancer Drug Sales Share by Country (2016-2027)
Figure 39. North America JAK Inhibitor Based Cancer Drug Revenue Share by Country (2016-2027)
Figure 40. United States JAK Inhibitor Based Cancer Drug Revenue (2016-2027) & (US$ Million)
Figure 41. Canada JAK Inhibitor Based Cancer Drug Revenue (2016-2027) & (US$ Million)
Figure 42. Europe JAK Inhibitor Based Cancer Drug Sales Market Share by Type (2016-2027)
Figure 43. Europe JAK Inhibitor Based Cancer Drug Revenue Market Share by Type (2016-2027)
Figure 44. Europe JAK Inhibitor Based Cancer Drug Sales Market Share by Application (2016-2027)
Figure 45. Europe JAK Inhibitor Based Cancer Drug Revenue Market Share by Application (2016-2027)
Figure 46. Europe JAK Inhibitor Based Cancer Drug Sales Share by Country (2016-2027)
Figure 47. Europe JAK Inhibitor Based Cancer Drug Revenue Share by Country (2016-2027)
Figure 48. Germany JAK Inhibitor Based Cancer Drug Revenue (2016-2027) & (US$ Million)
Figure 49. France JAK Inhibitor Based Cancer Drug Revenue (2016-2027) & (US$ Million)
Figure 50. U.K. JAK Inhibitor Based Cancer Drug Revenue (2016-2027) & (US$ Million)
Figure 51. Italy JAK Inhibitor Based Cancer Drug Revenue (2016-2027) & (US$ Million)
Figure 52. Russia JAK Inhibitor Based Cancer Drug Revenue (2016-2027) & (US$ Million)
Figure 53. Asia Pacific JAK Inhibitor Based Cancer Drug Sales Market Share by Type (2016-2027)
Figure 54. Asia Pacific JAK Inhibitor Based Cancer Drug Revenue Market Share by Type (2016-2027)
Figure 55. Asia Pacific JAK Inhibitor Based Cancer Drug Sales Market Share by Application (2016-2027)
Figure 56. Asia Pacific JAK Inhibitor Based Cancer Drug Revenue Market Share by Application (2016-2027)
Figure 57. Asia Pacific JAK Inhibitor Based Cancer Drug Sales Share by Region (2016-2027)
Figure 58. Asia Pacific JAK Inhibitor Based Cancer Drug Revenue Share by Region (2016-2027)
Figure 59. China JAK Inhibitor Based Cancer Drug Revenue (2016-2027) & (US$ Million)
Figure 60. Japan JAK Inhibitor Based Cancer Drug Revenue (2016-2027) & (US$ Million)
Figure 61. South Korea JAK Inhibitor Based Cancer Drug Revenue (2016-2027) & (US$ Million)
Figure 62. India JAK Inhibitor Based Cancer Drug Revenue (2016-2027) & (US$ Million)
Figure 63. Australia JAK Inhibitor Based Cancer Drug Revenue (2016-2027) & (US$ Million)
Figure 64. China Taiwan JAK Inhibitor Based Cancer Drug Revenue (2016-2027) & (US$ Million)
Figure 65. Indonesia JAK Inhibitor Based Cancer Drug Revenue (2016-2027) & (US$ Million)
Figure 66. Thailand JAK Inhibitor Based Cancer Drug Revenue (2016-2027) & (US$ Million)
Figure 67. Malaysia JAK Inhibitor Based Cancer Drug Revenue (2016-2027) & (US$ Million)
Figure 68. Latin America JAK Inhibitor Based Cancer Drug Sales Market Share by Type (2016-2027)
Figure 69. Latin America JAK Inhibitor Based Cancer Drug Revenue Market Share by Type (2016-2027)
Figure 70. Latin America JAK Inhibitor Based Cancer Drug Sales Market Share by Application (2016-2027)
Figure 71. Latin America JAK Inhibitor Based Cancer Drug Revenue Market Share by Application (2016-2027)
Figure 72. Latin America JAK Inhibitor Based Cancer Drug Sales Share by Country (2016-2027)
Figure 73. Latin America JAK Inhibitor Based Cancer Drug Revenue Share by Country (2016-2027)
Figure 74. Mexico JAK Inhibitor Based Cancer Drug Revenue (2016-2027) & (US$ Million)
Figure 75. Brazil JAK Inhibitor Based Cancer Drug Revenue (2016-2027) & (US$ Million)
Figure 76. Argentina JAK Inhibitor Based Cancer Drug Revenue (2016-2027) & (US$ Million)
Figure 77. Colombia JAK Inhibitor Based Cancer Drug Revenue (2016-2027) & (US$ Million)
Figure 78. Middle East and Africa JAK Inhibitor Based Cancer Drug Sales Market Share by Type (2016-2027)
Figure 79. Middle East and Africa JAK Inhibitor Based Cancer Drug Revenue Market Share by Type (2016-2027)
Figure 80. Middle East and Africa JAK Inhibitor Based Cancer Drug Sales Market Share by Application (2016-2027)
Figure 81. Middle East and Africa JAK Inhibitor Based Cancer Drug Revenue Market Share by Application (2016-2027)
Figure 82. Middle East and Africa JAK Inhibitor Based Cancer Drug Sales Share by Country (2016-2027)
Figure 83. Middle East and Africa JAK Inhibitor Based Cancer Drug Revenue Share by Country (2016-2027)
Figure 84. Turkey JAK Inhibitor Based Cancer Drug Revenue (2016-2027) & (US$ Million)
Figure 85. Saudi Arabia JAK Inhibitor Based Cancer Drug Revenue (2016-2027) & (US$ Million)
Figure 86. UAE JAK Inhibitor Based Cancer Drug Revenue (2016-2027) & (US$ Million)
Figure 87. JAK Inhibitor Based Cancer Drug Value Chain
Figure 88. JAK Inhibitor Based Cancer Drug Production Process
Figure 89. Channels of Distribution
Figure 90. Distributors Profiles
Figure 91. Bottom-up and Top-down Approaches for This Report
Figure 92. Data Triangulation
Figure 93. Key Executives Interviewed

---